A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Rituximab (Primary) ; Utomilumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2018 Planned End Date changed from 30 Sep 2024 to 30 Oct 2024.
- 05 Nov 2018 Planned primary completion date changed from 30 Sep 2021 to 30 Oct 2021.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.